AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9768370
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo once daily for 12 weeks
Trial: 7849541
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake Group 1 (409 +/‐ 21 mg calcium/day)
Trial: 7849541
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake Group 2 (663 +/‐ 16 mg calcium/day)
Trial: 7849541
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake Group 3 (950 +/‐ 32 mg calcium/day)
Trial: 7849541
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake Group 4 (1437 +/‐ 124 mg calcium/day)
Trial: 2660862
Drug: Early consolidation
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early consolidation with DATOP at lower dosage followed by maintenance chemotherapy
Trial: 21884028
Drug: Erythropoietin stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin stimulating agents (ESA) - epoetin alfa
Trial: 18264870
Drug: Recruitment strategies
RxNorm normalized name: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recruitment strategies for RCTs in drug and alcohol treatment
Trial: 17199193
Drug: Liposomal eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal eye spray (Tears Again)
Trial: 17199193
Drug: Eye gel
RxNorm normalized name: EYE GEL
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eye gel containing triglycerides (Liposic)
Trial: 15626589
Drug: Aspirin 50
RxNorm normalized name: aspirin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 50 mg daily for 5 consecutive days
Trial: 15626589
Drug: Colorectal cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colorectal cancer patients (without aspirin)
Trial: 12663271
Drug: PEG-OB (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-OB (80 mg weekly for 46 days)
Trial: 10052405
Drug: 8 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 microg/kg daily IL-10
Trial: 10052405
Drug: IL-10 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-10 treatment
Trial: 2150187
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg etodolac twice a day
Trial: 2150187
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg piroxicam once a day
Trial: 7191309
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 60 mg acemetacin
Trial: 30593268
Drug: Delayed-start GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed-start GnRH antagonist protocol with estrogen priming followed by early follicular-phase GnRH antagonist treatment for 7 days before ovarian stimulation with gonadotropin
Trial: 30593268
Drug: Standard GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard GnRH antagonist protocol with estrogen priming
Trial: 20571434
Drug: Aripiprazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (15 mg over a 14-day period)
Trial: 18717374
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of MT(Implant) and MT(Tooth) values
Trial: 16582545
Drug: Mg-rich mineral
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg-rich mineral water (281 mg/l)
Trial: 16582545
Drug: Mg-rich mineral
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg-rich mineral water (120 mg/l)
Trial: 16582545
Drug: Low mineralized
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low mineralized water (8 mg/l)
Trial: 16582545
Drug: Mg capsule
RxNorm normalized name: Tao 250mg Capsule
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg capsule (Magnesium‐Diasporal 150)
Trial: 15006256
Drug: RLX +
RxNorm normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RLX + low‐dose transdermal estrogen (RLX + E)
Trial: 8826517
Drug: Intravenous sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sufentanil 1 microgram/kg given 5 min before induction of anaesthesia (group A)
Trial: 8826517
Drug: Intravenous sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sufentanil 1 microgram/kg given after ligation of the round ligaments of the uterus (group B)
Trial: 1421710
Drug: Early high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early high dose chemotherapy and autologous bone marrow transplantation (ABMT) rescue
Trial: 6607596
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation (24 hr of clear liquids plus two major laxatives plus tap-water enemas)
Trial: 6607596
Drug: Colimmac lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colimmac lavage plus one major laxative
Trial: 28862032
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin pre-treatment (Control)
Trial: 29573941
Drug: Encorafenib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encorafenib plus binimetinib (oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily)
Trial: 29573941
Drug: Vemurafenib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vemurafenib (oral vemurafenib 960 mg twice daily)
Trial: 29573941
Drug: Encorafenib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encorafenib (oral encorafenib 300 mg once daily)
Trial: 26701234
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg I/mL iodine concentration
Trial: 26701234
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg I/mL iodine concentration
Trial: 24586292
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG (LGG) administration
Trial: 21038410
Drug: PEG IFN‐α2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG IFN‐α2a 180 μg subcutaneously weekly and weight‐based oral RBV 800 to 1,200 mg daily for 24 weeks
Trial: 21038410
Drug: PEG IFN‐α2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG IFN‐α2a 180 μg subcutaneously weekly and weight‐based oral RBV 800 to 1,200 mg daily for 48 weeks
Trial: 11563405
Drug: Dextromethorphan (DM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DM) at maximally tolerated doses administered orally prior to and continuing for 48 hours following surgery
Trial: 31400513
Drug: Mobile health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile health intervention including behavior change goals, daily text messages with feedback, web-based weight gain graphs, health coaching, and a Facebook support group.
Trial: 29160101
Drug: Peripheral nerve
RxNorm normalized name: Peripheral nerve antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral nerve block (7.5 mg/mL ropivacaine)
Trial: 22728756
Drug: Oseltamivir (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (75 mg once daily for those ≥13 years or weight‐based dosing for children 1‐12 years)
Trial: 19959338
Drug: Risperidone 6
RxNorm normalized name: risperidone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 6 mg/day plus mirtazapine 30 mg/day
Trial: 17972359
Drug: Risperidone 6
RxNorm normalized name: risperidone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 6 mg/day plus placebo
Trial: 18070637
Drug: Balanced injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced injection (steroid, lidocaine, bupivacaine, and bicarbonate, neutral pH)
Trial: 18070637
Drug: Standard injection
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard injection (steroid, lidocaine, and bupivacaine alone, acidic pH)
Trial: 6353278
Drug: Heparin (intravenous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (intravenous, given for 2 days)
Trial: 25052972
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg submucosal dexamethasone injection
Trial: 20222106
Drug: Denosumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (60 mg subcutaneous 6 monthly)
Trial: 20222106
Drug: Alendronate (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (70 mg oral weekly)
Trial: 16959304
Drug: Nadroparine 2850
RxNorm normalized name: Nadroparine
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparine 2850 units aXa/0.3 ml every 24 h during and 6 weeks after treatment
Trial: 27067081
Drug: Desmopressin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin treatment
Trial: 11472702
Drug: Heparin Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin Infusion Prior to Stenting
Trial: 2494620
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic (Control)
Trial: 26748347
Drug: n‐3 polyunsaturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 polyunsaturated fatty acid (PUFA) treatment (docosahexaenoic acid (DHA) and eicosapentaenoic acid) (Omacor/Lovaza, 4 g/day)
Trial: 17671229
Drug: Subtype B,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subtype B, E, and D immunoglobulin G capture immunoassay
Trial: 16223393
Drug: Ropivacaine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 10 mg with fentanyl 15 microg
Trial: 16223393
Drug: Bupivacaine 10
RxNorm normalized name: BUPivacaine 100 mg parenteral implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 10 mg with fentanyl 15 microg
Trial: 11962062
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antioxidants (vitamins E, C, beta-carotene) and minerals (zinc with copper)
Trial: 7016567
Drug: Dipyridamole in
RxNorm normalized name: Dipyridamole Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole in combination with fenoterol
Trial: 30461207
Drug: Amifostine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (200 mg/m2 IV)
Trial: 19168537
Drug: Ultrasound guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided corticosteroid and lidocaine injection in the subacromial bursa
Trial: 19168537
Drug: Corticosteroid and
RxNorm normalized name: Corticosteroid and/or corticosteroid derivative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid and lidocaine injection in the gluteal region
Trial: 21367933
Drug: rosiglitazone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (8 mg/d)
Trial: 17148569
Drug: metformin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin (2 g/d)
Trial: 10191748
Drug: Vancomycin prophylaxis
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin prophylaxis in patients with large blood loss (greater than 2 L)
Trial: 10191748
Drug: Vancomycin prophylaxis
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin prophylaxis in patients with small blood loss (less than 2 L)
Trial: 10191748
Drug: Preoperative 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative 1.5 gram-dose of vancomycin for patients weighing more than 90 kg
Trial: 2186854
Drug: Bestatin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bestatin (30 mg daily after evacuation)
Trial: 345342
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg glucagon
Trial: 345342
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg glucagon
Trial: 29788532
Drug: Epidural magnesium
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural magnesium sulphate (50 mg)
Trial: 26718373
Drug: Compound topical
RxNorm normalized name: benzoin compound TOPICAL TINCTURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound topical anesthetic (CTA)
Trial: 26718373
Drug: Needle injection
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle injection of local anesthetic
Trial: 22678100
Drug: Antiaggregation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiaggregation therapy
Trial: 18387222
Drug: Levocetirizine (LCTZ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine (LCTZ), 5 mg
Trial: 18387222
Drug: Montelukast (MLKT),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (MLKT), 10 mg
Trial: 10077045
Drug: Erythromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (1 g i.v. per day for 10 days)
Trial: 10077045
Drug: Erythromycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (2 g i.v. per day for 10 days)
Trial: 10077045
Drug: Erythromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (1 g oral per day for 1.5 to 8 months)
Trial: 10077045
Drug: Erythromycin (discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (discontinuation after 1.5 to 8 months)
Trial: 7561633
Drug: GHRH (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH (100 micrograms in 1 ml saline) injected as an i.v. bolus
Trial: 7561633
Drug: Hexarelin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexarelin (100 micrograms in 1 ml saline) injected as an i.v. bolus
Trial: 7561633
Drug: Hexarelin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexarelin (100 micrograms in 1 ml saline) plus GHRH (100 micrograms in 1 ml saline) injected as an i.v. bolus
Trial: 2185569
Drug: Alpha-tocopherol acetate
RxNorm normalized name: alpha-Tocopherol acetate
DrugBank: alpha-Tocopherol acetate (DB14003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpha-tocopherol acetate (600 mg)
Trial: 2185569
Drug: Placebo (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (600 mg)
Trial: 28177133
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + dietary supplementation of low-dose omega-3 PUFAs (6.25 mg eicosapentaenoic acid and 19.19 mg docosahexaenoic acid)
Trial: 28177133
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + dietary supplementation of low-dose omega-3 PUFAs
Trial: 25148566
Drug: Take Charge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take Charge of Your Life drug prevention program
Trial: 19197383
Drug: 7.5 microg
RxNorm normalized name: Levonorgestrel 37.5 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 microg dose of MF59-adjuvanted H5N1 vaccine
Trial: 19197383
Drug: 15 microg
RxNorm normalized name: Tafluprost 15 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg dose of MF59-adjuvanted H5N1 vaccine
Trial: 19197383
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations of MF59-adjuvanted H5N1 vaccine
Trial: 12751274
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg M100240 via short intravenous infusion
Trial: 12751274
Drug: Oral immediate-release
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immediate-release tablet administration
Trial: 12751274
Drug: Oral Enterion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Enterion capsule delivery to the proximal small bowel
Trial: 12751274
Drug: Oral immediate-release
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immediate-release formulation of M100240
Trial: 11083625
Drug: Ciprofloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (400 mg t.i.d. for at least 72 h followed by 750 mg b.i.d. orally)
Trial: 11083625
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g t.i.d. intravenously) plus Amikacin (500 mg b.i.d. intravenously)
Trial: 7594063
Drug: Propionyl-L-carnitine
RxNorm normalized name: GLYCINE PROPIONYL-L-CARNITINE
DrugBank: Levocarnitine propionate (DB15980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionyl-L-carnitine
Trial: 2854609
Drug: Sublingual prazepam
RxNorm normalized name: prazepam
DrugBank: Prazepam (DB01588)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual prazepam 20 mg
Trial: 2854609
Drug: Oral prazepam
RxNorm normalized name: prazepam
DrugBank: Prazepam (DB01588)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prazepam 20 mg
Trial: 31330502
Drug: Suspension Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension Training (ST)
Trial: 20398849
Drug: Postoperative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative therapy with concurrent chemoradiotherapy plus fluoropyrimidine-based chemotherapy
Trial: 18636998
Drug: Usual addiction
RxNorm normalized name: DRUGS USED IN ADDICTIVE DISORDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual addiction treatment (control group)
Trial: 10660730
Drug: Chemotherapy based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy based on evidence-based medicine (EBM)
Trial: 9138996
Drug: Measurements (CC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurements (CC, CA, HA, (CA‐HA) x 100/CA)
Trial: 1827010
Drug: Isradipine 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 1.25 to 2.5 mg twice daily
Trial: 6291439
Drug: Conjugated estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogen therapy (0.6 mg/d)
Trial: 6291439
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and low-dose treatment groups
Trial: 20340011
Drug: Citalopram (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20-40 mg/d)
Trial: 19056706
Drug: Vitamin/nutriceutical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin/nutriceutical formulation (folate, vitamin B12, alpha‐tocopherol, S‐adenosyl methionine, N‐acetyl cysteine, and acetyl‐L‐carnitine)
Trial: 19056706
Drug: Vitamin/nutriceutical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin/nutriceutical formulation
Trial: 15026402
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (HTS) - 250 mL of 7.5% saline
Trial: 15026402
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - 250 mL of Ringer's lactate solution
Trial: 9664090
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg once daily at bedtime for 12 weeks
Trial: 7927227
Drug: Emergency medical
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency medical therapy (intravenous vasopressin and esophageal balloon tamponade) followed by elective portacaval shunt
Trial: 9184881
Drug: Emergency medical
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency medical therapy
Trial: 7927227
Drug: Emergency medical
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency medical therapy followed by elective shunt
Trial: 3056505
Drug: 1‐mg gemeprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐mg gemeprost (Cervagem) pessary
Trial: 24886272
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg once daily for 40 weeks
Trial: 31694122
Drug: Exercise rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise rehabilitation training and routine therapy
Trial: 31694122
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment only (physical therapy and NSAIDs)
Trial: 9108457
Drug: GM‐CSF gene‐transduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF gene‐transduced vaccines
Trial: 9108457
Drug: Nontransduced vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nontransduced vaccines
Trial: 9108457
Drug: GM‐CSF gene‐transduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF gene‐transduced vaccine
Trial: 2860136
Drug: Propranolol, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 20 to 30 mg/day
Trial: 2860136
Drug: Lorazepam, 2
RxNorm normalized name: Lorazepam, 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam, 2 mg/day
Trial: 23992231
Drug: 3125 U/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3125 U/mL heparin saline (HS)